Table 1. Clinical and demographic data of the 10 patients with MS.

Patient	Gender	Age in years	Disease duration in years	Previous treatment	Treatment gap in months	EDSS at baseline	EDSS after 12 months	Relapses during 12 months prior to fingolimod	Relapses during 12-month follow-up
Pat01	female	43	20	IFN-beta-1a sc	38	4.0	3.0	1	0
Pat02	female	26	3	IFN-beta-1b sc	1	1.5	2.0	2	0
Pat03	female	29	5	glatiramer acetate	<1	2.5	1.5	3	0
Pat04	female	43	1	IFN-beta-1a im	1	4.0	3.5	2	0
Pat05	female	45	12	IFN-beta-1a im	2	3.0	3.0	3	0
Pat06	female	33	2	glatiramer acetate	<1	2.5	5.5	2	2
Pat07	female	46	9	IFN-beta-1b sc	<1	4.0	4.0	1	0
Pat08	male	33	4	IFN-beta-1a sc	<1	3.0	6.0	1	3
Pat09	male	46	15	IFN-beta-1b sc	<1	3.5	2.0	1	0
Pat10	male	37	9	glatiramer acetate	1	5.5	4.0	1	0
Median (range)		40 (26–46)	7 (1–20)		1 (0–38)	3.3 (1.5–5.5)	3.3 (1.5–6.0)	1.5 (1–3)	0 (0–3)

The table provides gender, age at study onset, disease duration and previous treatment for each patient selected for the transcriptome profiling. The time span between the last injection of the previous immunomodulatory treatment and the first oral administration of fingolimod is given as well (treatment gap). Additionally, the EDSS and the number of relapses before the start of fingolimod therapy (baseline) as well as after a clinical follow-up period of one year are given. EDSS: Expanded Disability Status Scale, IFN: interferon, im: intramuscular, sc: subcutaneous.